Dandan Liu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Dandan Liu has a total of 175 co-authors. Here are the top co-authors by number of shared publications:
- Angela L. Jefferson
Vanderbilt Memory and Alzheimer's Center Vanderbilt University School of Medicine Nashville Tennessee USA
7 shared publications - Kimberly R. Pechman
Vanderbilt University Medical Center, Vanderbilt Memory and Alzheimer’s Center, Nashville, Tennessee, United States
7 shared publications - Timothy J. Hohman
Vanderbilt Memory & Alzheimer’s Center, Vanderbilt Health, Nashville, TN, USA
7 shared publications - Bennett A. Landman
Department of Electrical and Computer Engineering Vanderbilt University Nashville Tennessee USA
4 shared publications Katherine A. Gifford
Department of Anatomy & Neurobiology Boston University School of Medicine Boston Massachusetts USA
4 shared publications- Alan B. Storrow
Department of Emergency Medicine, Vanderbilt University Medical Center, Nashville, USA
3 shared publications
Latest Publications
- 1 November 2026
- Published by Wolters Kluwer Health in Stroke
- Vol. 57 (11) , 3245-3258
Arterial Spin Labeling Hemodynamic Indices Relate to Cognitive and Small Vessel Disease Trajectories Over 11 Years
BACKGROUND: Hemodynamic insufficiency may contribute to the development of neuroimaging signs of cerebral small vessel disease (SVD). The arterial spin labeling (ASL) spatial coefficient of variation (ASL-sCoV) is a proxy marker of arterial transit time and may better capture SVD-related hemodynamic disturbances compared with ASL-derived cerebral blood flow. We investigated ASL-derived hemodynamic indices in relation to cognition and neuroimaging markers of SVD over an 11-year follow-up period. METHODS: Participants without dementia or stroke were enrolled in the Vanderbilt Memory and Aging Project, a longitudinal observational cohort study in Nashville, TN. Participants underwent serial multimodal 3T brain magnetic resonance imaging to quantify SVD burden and neuropsychological assessment from 2012 to 2024 (4.9±3.5 years mean follow-up). Pseudo-continuous ASL assessed cerebral blood flow and ASL-sCoV in total gray matter. Baseline ASL-sCoV and cerebral blood flow were individually related to the cross-sectional burden and longitudinal trajectory of each SVD neuroimaging marker (white matter hyperintensities, enlarged perivascular spaces, cerebral microbleeds, and lacunar infarcts) and cognitive performances using linear and linear mixed-effects regression models. Models were adjusted for demographics, cognitive status, Framingham Stroke Risk Profile (minus age), apolipoprotein E -ε4 status, intracranial volume (for SVD outcomes), and follow-up time (for longitudinal models). RESULTS: Among participants (n=667, 68±9 years, 18% mild cognitive impairment, 51% female), higher ASL-sCoV was cross-sectionally associated with SVD markers, including white matter hyperintensities and enlarged perivascular spaces ( p FDR -valuesp FDR =0.03) and accelerated decline in executive function, information processing, language, and visuospatial performances ( P 0.05) or longitudinally ( p FDR -values>0.06). CONCLUSIONS: ASL-sCoV may serve as an important hemodynamic measure for identifying perfusion deficits tied to SVD burden and progression. Readily derived from existing ASL data sets, ASL-sCoV could provide substantial insight into the longitudinal clinical consequences of SVD.
- 1 November 2026
- Published by Wolters Kluwer Health in Stroke
- Vol. 57 (11) , 3245-3258
Arterial Spin Labeling Hemodynamic Indices Relate to Cognitive and Small Vessel Disease Trajectories Over 11 Years
BACKGROUND: Hemodynamic insufficiency may contribute to the development of neuroimaging signs of cerebral small vessel disease (SVD). The arterial spin labeling (ASL) spatial coefficient of variation (ASL-sCoV) is a proxy marker of arterial transit time and may better capture SVD-related hemodynamic disturbances compared with ASL-derived cerebral blood flow. We investigated ASL-derived hemodynamic indices in relation to cognition and neuroimaging markers of SVD over an 11-year follow-up period. METHODS: Participants without dementia or stroke were enrolled in the Vanderbilt Memory and Aging Project, a longitudinal observational cohort study in Nashville, TN. Participants underwent serial multimodal 3T brain magnetic resonance imaging to quantify SVD burden and neuropsychological assessment from 2012 to 2024 (4.9±3.5 years mean follow-up). Pseudo-continuous ASL assessed cerebral blood flow and ASL-sCoV in total gray matter. Baseline ASL-sCoV and cerebral blood flow were individually related to the cross-sectional burden and longitudinal trajectory of each SVD neuroimaging marker (white matter hyperintensities, enlarged perivascular spaces, cerebral microbleeds, and lacunar infarcts) and cognitive performances using linear and linear mixed-effects regression models. Models were adjusted for demographics, cognitive status, Framingham Stroke Risk Profile (minus age), apolipoprotein E -ε4 status, intracranial volume (for SVD outcomes), and follow-up time (for longitudinal models). RESULTS: Among participants (n=667, 68±9 years, 18% mild cognitive impairment, 51% female), higher ASL-sCoV was cross-sectionally associated with SVD markers, including white matter hyperintensities and enlarged perivascular spaces ( p FDR -valuesp FDR =0.03) and accelerated decline in executive function, information processing, language, and visuospatial performances ( P 0.05) or longitudinally ( p FDR -values>0.06). CONCLUSIONS: ASL-sCoV may serve as an important hemodynamic measure for identifying perfusion deficits tied to SVD burden and progression. Readily derived from existing ASL data sets, ASL-sCoV could provide substantial insight into the longitudinal clinical consequences of SVD.
- Open Access
- 11 September 2026
- Published by Wiley in Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
- Vol. 46 (10)
Safety of Nonsteroidal Anti‐Inflammatory Drug Use in Traumatic Brain Injury
Background: Use of nonsteroidal anti‐inflammatory drugs (NSAIDs) after a traumatic brain injury (TBI) is controversial due to potential worsening of an intracranial hemorrhage (ICH). This study evaluated if NSAID use within 14 days of TBI was associated with a clinically significant progression of intracranial bleed (PIB). Methods: A retrospective, propensity score‐weighted study was conducted in adult patients with a TBI admitted to an American College of Surgeons Certified Level I Trauma Center. The NSAID group included patients who received at least one dose of an NSAID within 14 days of injury while admitted. The control group included patients who did not receive NSAIDs. The primary end point was incidence of a clinically significant PIB (decrease in the Glasgow Coma Score (GCS) > 2 and an increased or new ICH). Secondary outcomes included need for additional neurosurgical intervention and PIB on imaging regardless of GCS change. Results: 978 patients were included: 284 in the NSAID group and 694 in the control group. Most patients had an Abbreviated Injury Score head > 2 (88%) and a subdural hematoma (57%). Fifty‐two percent of patients had a mixed bleed. A clinically significant PIB occurred in 0.35% in the NSAID group and 1.2% in the control group (Hazards Ratio 0.1, 95% Confidence Interval 0.01–0.82, p = 0.032). There was no difference in additional neurosurgical operations or PIB regardless of GCS change. In the NSAID group, there was no significant difference in time from admission to NSAID administration between patients who experienced a PIB and those who did not have a PIB (1.9 days vs. 4.7 days, respectively, p = 0.06). Conclusion: In this single‐center, retrospective, propensity score‐weighted study, NSAIDs were not associated with an increased risk of clinically significant PIB in patients with acute TBI when administered within 14 days of injury. NSAIDs appear safe in the acute phase post‐TBI. Prospective studies are needed to validate our results.
- 11 September 2026
- Published by Wiley in Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
- Vol. 46 (10)
Open AccessSafety of Nonsteroidal Anti‐Inflammatory Drug Use in Traumatic Brain Injury
Background: Use of nonsteroidal anti‐inflammatory drugs (NSAIDs) after a traumatic brain injury (TBI) is controversial due to potential worsening of an intracranial hemorrhage (ICH). This study evaluated if NSAID use within 14 days of TBI was associated with a clinically significant progression of intracranial bleed (PIB). Methods: A retrospective, propensity score‐weighted study was conducted in adult patients with a TBI admitted to an American College of Surgeons Certified Level I Trauma Center. The NSAID group included patients who received at least one dose of an NSAID within 14 days of injury while admitted. The control group included patients who did not receive NSAIDs. The primary end point was incidence of a clinically significant PIB (decrease in the Glasgow Coma Score (GCS) > 2 and an increased or new ICH). Secondary outcomes included need for additional neurosurgical intervention and PIB on imaging regardless of GCS change. Results: 978 patients were included: 284 in the NSAID group and 694 in the control group. Most patients had an Abbreviated Injury Score head > 2 (88%) and a subdural hematoma (57%). Fifty‐two percent of patients had a mixed bleed. A clinically significant PIB occurred in 0.35% in the NSAID group and 1.2% in the control group (Hazards Ratio 0.1, 95% Confidence Interval 0.01–0.82, p = 0.032). There was no difference in additional neurosurgical operations or PIB regardless of GCS change. In the NSAID group, there was no significant difference in time from admission to NSAID administration between patients who experienced a PIB and those who did not have a PIB (1.9 days vs. 4.7 days, respectively, p = 0.06). Conclusion: In this single‐center, retrospective, propensity score‐weighted study, NSAIDs were not associated with an increased risk of clinically significant PIB in patients with acute TBI when administered within 14 days of injury. NSAIDs appear safe in the acute phase post‐TBI. Prospective studies are needed to validate our results.
- Open Access
- 22 July 2026
- Published by Elsevier in Magnetic Resonance Imaging
- Vol. 134, 110749
A comparative evaluation of multiple enlarged perivascular space segmentation tools
- 22 July 2026
- Published by Elsevier in Magnetic Resonance Imaging
- Vol. 134, 110749
Open AccessA comparative evaluation of multiple enlarged perivascular space segmentation tools
- Open Access
- 12 May 2026
- Published by Wolters Kluwer Health in Neurology
- Vol. 106 (9) , e214803
Association of MRI-Visible Perivascular Spaces With Longitudinal Cognitive Decline Over a Decade
Cerebral small vessel disease (SVD) is the most common vascular contributor to dementia. SVD markers often coexist, contributing to difficulty assessing their independent contributions to cognitive domains. MRI-visible perivascular spaces (PVSs) are an emerging SVD marker visualized by MRI. We previously showed that basal ganglia PVSs cross-sectionally contribute to worse cognition, independent of other SVD markers. To further characterize the clinical relevance of PVS, we studied its role as a unique SVD marker of longitudinal cognitive decline. Participants without stroke or dementia were included in the Vanderbilt Memory and Aging Project, a longitudinal observational cohort study based in Nashville, TN. Participants completed 3T MRI at study entry to measure SVD burden (PVS volume fraction, white matter hyperintensities volume, lacune counts, and cerebral microbleeds counts). PVS volumes were segmented using a deep learning algorithm. Participants underwent comprehensive serial neuropsychological testing over an 11-year follow-up period (mean follow-up = 4.9 ± 3.1 years). Each SVD marker was related to longitudinal neuropsychological performances using a linear mixed-effects model adjusting for age, sex, race/ethnicity, education, baseline cognitive status, apolipoprotein E-ε4 presence, Framingham Stroke Risk Profile, and intracranial volume. Head-to-head comparisons simultaneously tested multiple statistically significant SVD markers. Among participants (n = 750, age 68 ± 9 years, 52% female), higher basal ganglia PVS burden at baseline was associated with worse longitudinal performances in Boston Naming Test (β = -29.63; 95% CI -56.66 to -2.60), Animal Naming (β = -33.09; 95% CI -65.66 to -0.51), Wechsler Adult Intelligence Scale IV Coding (β = -86.36; 95% CI -150.9 to -21.82), executive function composite (β = -9.51; 95% CI -14.33 to -4.68), Hooper Visual Organization Test (β = -26.06; 95% CI -50.53 to -1.59), and episodic memory composite (β = -7.05; 95% CI -11.9 to -2.21). In head-to-head comparisons, basal ganglia PVS remained independent associations with executive function composite (β = -7.47; 95% CI -12.84 to -2.10) and Hooper Visual Organization Test (β = -22.11; 95% CI -42.38 to -1.85). Basal ganglia PVS burden independently contributes to worse longitudinal executive function and visuospatial skills independent of other SVD markers, highlighting PVS as an emerging marker of domain-specific cognitive decline in aging. Although causation cannot be established, findings further support PVS as a vascular contributor to deep brain structure damage underlying cognitive decline over time.
- 12 May 2026
- Published by Wolters Kluwer Health in Neurology
- Vol. 106 (9) , e214803
Open AccessAssociation of MRI-Visible Perivascular Spaces With Longitudinal Cognitive Decline Over a Decade
Cerebral small vessel disease (SVD) is the most common vascular contributor to dementia. SVD markers often coexist, contributing to difficulty assessing their independent contributions to cognitive domains. MRI-visible perivascular spaces (PVSs) are an emerging SVD marker visualized by MRI. We previously showed that basal ganglia PVSs cross-sectionally contribute to worse cognition, independent of other SVD markers. To further characterize the clinical relevance of PVS, we studied its role as a unique SVD marker of longitudinal cognitive decline. Participants without stroke or dementia were included in the Vanderbilt Memory and Aging Project, a longitudinal observational cohort study based in Nashville, TN. Participants completed 3T MRI at study entry to measure SVD burden (PVS volume fraction, white matter hyperintensities volume, lacune counts, and cerebral microbleeds counts). PVS volumes were segmented using a deep learning algorithm. Participants underwent comprehensive serial neuropsychological testing over an 11-year follow-up period (mean follow-up = 4.9 ± 3.1 years). Each SVD marker was related to longitudinal neuropsychological performances using a linear mixed-effects model adjusting for age, sex, race/ethnicity, education, baseline cognitive status, apolipoprotein E-ε4 presence, Framingham Stroke Risk Profile, and intracranial volume. Head-to-head comparisons simultaneously tested multiple statistically significant SVD markers. Among participants (n = 750, age 68 ± 9 years, 52% female), higher basal ganglia PVS burden at baseline was associated with worse longitudinal performances in Boston Naming Test (β = -29.63; 95% CI -56.66 to -2.60), Animal Naming (β = -33.09; 95% CI -65.66 to -0.51), Wechsler Adult Intelligence Scale IV Coding (β = -86.36; 95% CI -150.9 to -21.82), executive function composite (β = -9.51; 95% CI -14.33 to -4.68), Hooper Visual Organization Test (β = -26.06; 95% CI -50.53 to -1.59), and episodic memory composite (β = -7.05; 95% CI -11.9 to -2.21). In head-to-head comparisons, basal ganglia PVS remained independent associations with executive function composite (β = -7.47; 95% CI -12.84 to -2.10) and Hooper Visual Organization Test (β = -22.11; 95% CI -42.38 to -1.85). Basal ganglia PVS burden independently contributes to worse longitudinal executive function and visuospatial skills independent of other SVD markers, highlighting PVS as an emerging marker of domain-specific cognitive decline in aging. Although causation cannot be established, findings further support PVS as a vascular contributor to deep brain structure damage underlying cognitive decline over time.
- Open Access
- 5 May 2026
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 15 (9) , e043186
Plasma von Willebrand Factor and ADAMTS13 Interact With APOE ‐ε4 in Predicting Longitudinal Brain Atrophy and Cognitive Decline Over a 9‐Year Follow‐Up
Background: Von Willebrand factor (VWF) and ADAMTS13 (a disintegrin and metalloproteinase with thrombospondin type 1 motif, 13) are linked to dementia risk, and limited evidence suggests apolipoprotein E ( APOE )‐ε4 alters VWF release. This study assessed whether baseline VWF and ADAMTS13 levels predict neurodegeneration and cognitive decline and evaluated effect modification by APOE‐ε4 carriership. Methods: Vanderbilt Memory and Aging Project cohort participants (n=332, 73±7 years, 59% male) completed serial blood draw, neuropsychological assessment, and brain magnetic resonance imaging over 6.4 years (range 1.4–9.7 years). Baseline plasma VWF and ADAMTS13 levels were quantified using mass spectrometry and Olink. Fully adjusted linear mixed‐effects models related protein×time and protein×APOE‐ε4×time interaction terms to longitudinal brain magnetic resonance imaging and neuropsychological outcomes. Results: Lower baseline ADAMTS13 predicted faster declines in language (β=0.11, P =0.01), information processing speed (β=0.27, P =0.001), executive function (β=0.01, P =0.03), episodic memory (β=0.01, P =0.03), and visuospatial ability (β=0.11, P =0.001) and faster increases in global (β=−0.29, P =0.01) and frontal (β=−0.17, P =0.01) white matter hyperintensity volumes. Associations between ADAMTS13 and faster rates of cognitive decline and white matter injury were driven by APOE ‐ε4 carriers. Models relating VWF to longitudinal outcomes were null. APOE ‐ε4 interacted with VWF on longitudinal gray matter volumetric outcomes, such that faster rates of global gray matter atrophy were observed with higher baseline VWF levels among APOE ‐ε4 noncarriers only (β=−1530.5, P APOE ‐ε4 allele.
- 5 May 2026
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 15 (9) , e043186
Open AccessPlasma von Willebrand Factor and ADAMTS13 Interact With APOE ‐ε4 in Predicting Longitudinal Brain Atrophy and Cognitive Decline Over a 9‐Year Follow‐Up
Background: Von Willebrand factor (VWF) and ADAMTS13 (a disintegrin and metalloproteinase with thrombospondin type 1 motif, 13) are linked to dementia risk, and limited evidence suggests apolipoprotein E ( APOE )‐ε4 alters VWF release. This study assessed whether baseline VWF and ADAMTS13 levels predict neurodegeneration and cognitive decline and evaluated effect modification by APOE‐ε4 carriership. Methods: Vanderbilt Memory and Aging Project cohort participants (n=332, 73±7 years, 59% male) completed serial blood draw, neuropsychological assessment, and brain magnetic resonance imaging over 6.4 years (range 1.4–9.7 years). Baseline plasma VWF and ADAMTS13 levels were quantified using mass spectrometry and Olink. Fully adjusted linear mixed‐effects models related protein×time and protein×APOE‐ε4×time interaction terms to longitudinal brain magnetic resonance imaging and neuropsychological outcomes. Results: Lower baseline ADAMTS13 predicted faster declines in language (β=0.11, P =0.01), information processing speed (β=0.27, P =0.001), executive function (β=0.01, P =0.03), episodic memory (β=0.01, P =0.03), and visuospatial ability (β=0.11, P =0.001) and faster increases in global (β=−0.29, P =0.01) and frontal (β=−0.17, P =0.01) white matter hyperintensity volumes. Associations between ADAMTS13 and faster rates of cognitive decline and white matter injury were driven by APOE ‐ε4 carriers. Models relating VWF to longitudinal outcomes were null. APOE ‐ε4 interacted with VWF on longitudinal gray matter volumetric outcomes, such that faster rates of global gray matter atrophy were observed with higher baseline VWF levels among APOE ‐ε4 noncarriers only (β=−1530.5, P APOE ‐ε4 allele.
- Open Access
- 5 December 2025
- Published by Elsevier in Brain Research
- Vol. 1872, 150092
An organ-on-a-chip investigation into dose-dependent, temporal dynamic effects of radiosurgery on the blood–brain barrier and its immunological response
- 5 December 2025
- Published by Elsevier in Brain Research
- Vol. 1872, 150092
Open AccessAn organ-on-a-chip investigation into dose-dependent, temporal dynamic effects of radiosurgery on the blood–brain barrier and its immunological response
- Open Access
- 19 June 2025
- Published by Wiley in Alzheimer's & Dementia
- Vol. 21 (6) , e70335
The dynamics of cognitive decline toward Alzheimer's disease progression: Results from ADSP‐PHC's harmonized cognitive composites
INTRODUCTION: Accurately assessing the temporal order of cognitive decline across multiple domains is critical in Alzheimer's disease (AD). Existing literature presents controversial conclusions likely due to the use of a single cohort and different analytical strategies.METHODS: Harmonized composite cognitive measures in memory, language, and executive functions from 13 cohorts in the Alzheimer's Disease Sequencing Project Phenotype Harmonization Consortium (ADSP‐PHC) were used. A double anchoring events–based sigmoidal mixed model was developed using time to incident AD diagnosis as the time scale.RESULTS: In general, decline in memory occurred before decline in language, followed by decline in executive function. This temporal order generally persisted within each subgroup of apolipoprotein E ε4 carrier status, sex, and race/ethnicity.DISCUSSION: This study demonstrated the use of harmonized data across multiple cohorts to characterize the temporal order of cognitive decline along AD progression. Using time to incident AD diagnosis as the time scale can enhance research reproducibility and clinical practice.Highlights: Alzheimer's Disease Sequencing Project Phenotype Harmonization Consortium's harmonized composite cognitive measures from 13 cohort studies fitted with a novel double anchoring event‐based sigmoidal mixed model reveal the following temporal order of cognitive decline toward AD progression: memory, language, and executive function. If only investigated using individual cohort studies, the temporal order of cognitive decline would vary due to the underlying heterogeneities across studies. This temporal order generally persisted within each subgroup of apolipoprotein E ε4 carrier status, sex, and race/ethnicity.
- 19 June 2025
- Published by Wiley in Alzheimer's & Dementia
- Vol. 21 (6) , e70335
Open AccessThe dynamics of cognitive decline toward Alzheimer's disease progression: Results from ADSP‐PHC's harmonized cognitive composites
INTRODUCTION: Accurately assessing the temporal order of cognitive decline across multiple domains is critical in Alzheimer's disease (AD). Existing literature presents controversial conclusions likely due to the use of a single cohort and different analytical strategies.METHODS: Harmonized composite cognitive measures in memory, language, and executive functions from 13 cohorts in the Alzheimer's Disease Sequencing Project Phenotype Harmonization Consortium (ADSP‐PHC) were used. A double anchoring events–based sigmoidal mixed model was developed using time to incident AD diagnosis as the time scale.RESULTS: In general, decline in memory occurred before decline in language, followed by decline in executive function. This temporal order generally persisted within each subgroup of apolipoprotein E ε4 carrier status, sex, and race/ethnicity.DISCUSSION: This study demonstrated the use of harmonized data across multiple cohorts to characterize the temporal order of cognitive decline along AD progression. Using time to incident AD diagnosis as the time scale can enhance research reproducibility and clinical practice.Highlights: Alzheimer's Disease Sequencing Project Phenotype Harmonization Consortium's harmonized composite cognitive measures from 13 cohort studies fitted with a novel double anchoring event‐based sigmoidal mixed model reveal the following temporal order of cognitive decline toward AD progression: memory, language, and executive function. If only investigated using individual cohort studies, the temporal order of cognitive decline would vary due to the underlying heterogeneities across studies. This temporal order generally persisted within each subgroup of apolipoprotein E ε4 carrier status, sex, and race/ethnicity.
- Open Access
The Dynamics of Cognitive Decline towards Alzheimer’s Disease Progression: Results from ADSP-PHC’s Harmonized Cognitive Composites
INTRODUCTION: Accurately assessing temporal order of cognitive decline across multiple domains is critical in Alzheimer’s disease (AD). Existing literature presented controversial conclusions likely due to the use of a single cohort and different analytical strategies. METHODS: Harmonized composite cognitive measures in memory, language and executive functions from 13 cohorts in the ADSP-PHC data are used. A novel double anchoring events-based sigmoidal mixed model was developed using time to the incident of AD diagnosis as the time scale. RESULTS: Decline in memory occurred before decline in language which was followed by the decline in executive function. Throughout the entire AD continuum, APOE- ε 4 non-carriers and non-Hispanic Whites showed better memory performance, respectively, in all three cognitive domains. DISCUSSION: Using harmonized data across multiple cohorts is the key to accurately characterizing the temporal order of AD biomarkers. Time to incident AD diagnosis should be used as the time scale for reproducibility purposes.
Open AccessThe Dynamics of Cognitive Decline towards Alzheimer’s Disease Progression: Results from ADSP-PHC’s Harmonized Cognitive Composites
INTRODUCTION: Accurately assessing temporal order of cognitive decline across multiple domains is critical in Alzheimer’s disease (AD). Existing literature presented controversial conclusions likely due to the use of a single cohort and different analytical strategies. METHODS: Harmonized composite cognitive measures in memory, language and executive functions from 13 cohorts in the ADSP-PHC data are used. A novel double anchoring events-based sigmoidal mixed model was developed using time to the incident of AD diagnosis as the time scale. RESULTS: Decline in memory occurred before decline in language which was followed by the decline in executive function. Throughout the entire AD continuum, APOE- ε 4 non-carriers and non-Hispanic Whites showed better memory performance, respectively, in all three cognitive domains. DISCUSSION: Using harmonized data across multiple cohorts is the key to accurately characterizing the temporal order of AD biomarkers. Time to incident AD diagnosis should be used as the time scale for reproducibility purposes.
- Open Access
- 12 September 2024
- Published by Wiley in Statistics in Medicine
- Vol. 43 (26) , 4984-4999
Addressing the implementation challenge of risk prediction model due to missing risk factors: The submodel approximation approach
Clinical prediction models have been widely acknowledged as informative tools providing evidence‐based support for clinical decision making. However, prediction models are often underused in clinical practice due to many reasons including missing information upon real‐time risk calculation in electronic health records (EHR) system. Existing literature to address this challenge focuses on statistical comparison of various approaches while overlooking the feasibility of their implementation in EHR. In this article, we propose a novel and feasible submodel approach to address this challenge for prediction models developed using the model approximation (also termed “preconditioning”) method. The proposed submodel coefficients are equivalent to the corresponding original prediction model coefficients plus a correction factor. Comprehensive simulations were conducted to assess the performance of the proposed method and compared with the existing “one‐step‐sweep” approach as well as the imputation approach. In general, the simulation results show the preconditioning‐based submodel approach is robust to various heterogeneity scenarios and is comparable to the imputation‐based approach, while the “one‐step‐sweep” approach is less robust under certain heterogeneity scenarios. The proposed method was applied to facilitate real‐time implementation of a prediction model to identify emergency department patients with acute heart failure who can be safely discharged home.
- 12 September 2024
- Published by Wiley in Statistics in Medicine
- Vol. 43 (26) , 4984-4999
Open AccessAddressing the implementation challenge of risk prediction model due to missing risk factors: The submodel approximation approach
Clinical prediction models have been widely acknowledged as informative tools providing evidence‐based support for clinical decision making. However, prediction models are often underused in clinical practice due to many reasons including missing information upon real‐time risk calculation in electronic health records (EHR) system. Existing literature to address this challenge focuses on statistical comparison of various approaches while overlooking the feasibility of their implementation in EHR. In this article, we propose a novel and feasible submodel approach to address this challenge for prediction models developed using the model approximation (also termed “preconditioning”) method. The proposed submodel coefficients are equivalent to the corresponding original prediction model coefficients plus a correction factor. Comprehensive simulations were conducted to assess the performance of the proposed method and compared with the existing “one‐step‐sweep” approach as well as the imputation approach. In general, the simulation results show the preconditioning‐based submodel approach is robust to various heterogeneity scenarios and is comparable to the imputation‐based approach, while the “one‐step‐sweep” approach is less robust under certain heterogeneity scenarios. The proposed method was applied to facilitate real‐time implementation of a prediction model to identify emergency department patients with acute heart failure who can be safely discharged home.